GKOS News and Press, Glaukos Corporation

2024-07-10 12:52:04 ET More on Glaukos, Intuitive Surgical, etc. Glaukos Stock: Still Unproven Whether A New Bull Market Has Begun Tandem Diabetes Care: Recent Rally Fully Deserved, Likely More Upside Here Intuitive Surgical: Hope For A Resurgence In Operational Leve...

Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...

Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...

2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its 2.75% Convertible Senior Notes due 2027 (the...

2024-06-10 13:27:45 ET More on iShares U.S. Medical Devices ETF: IHI: Despite Steady Returns At Current Prices, ETF Is Fairly Valued IHI: Technological Advances Will Continue Carrying This High-Performing Medical ETF The most crowded longs and shorts in U.S. Med-Tech...

2024-05-30 09:30:58 ET Summary Glaukos Corporation has experienced two significant technical analysis developments over the past 20 weeks. GKOS stock price gains are being driven by strong top-line growth, but profitability trends continue to disappoint. A trailing stop-loss o...

2024-05-21 10:00:21 ET Matt O'Brien from Piper Sandler issued a price target of $110.00 for GKOS on 2024-05-21 08:48:00. The adjusted price target was set to $110.00. At the time of the announcement, GKOS was trading at $107.94. The overall price target consensus is at $...

2024-05-06 10:07:39 ET Glaukos ( NYSE: GKOS ) stock is up on upgrade to Buy from Hold at Jefferies on strong iDose Outlook.... Read the full article on Seeking Alpha For further details see: Glaukos rises on upgrade to Buy at Jefferies